French pharmaceutical giant Sanofi has announced a major acquisition, revealing plans to buy U.S.-based biotech company Blueprint Medicines for approximately $9.1 billion in cash. The move aims to strengthen Sanofi’s position in the treatment of rare immunological diseases and marks a significant expansion of its global immunology portfolio.
The deal includes a per-share purchase price of $129, representing a 27% premium over Blueprint’s closing stock price on Friday. According to Sanofi, this acquisition will reinforce its transformation into a leading immunology-focused company and expand its pipeline of treatments targeting rare conditions.
Sanofi, which operates its largest German production facility in Frankfurt, emphasized the strategic importance of the acquisition. “The planned acquisition of Blueprint Medicines represents a strategic step forward for our rare disease and immunology portfolios,” said Sanofi CEO Paul Hudson. “It broadens our pipeline and accelerates our evolution into a global immunology leader.”
Focus on Rare Disease Treatment
With the acquisition, Sanofi will gain access to Avapritinib, a medication already approved in both the United States and European Union. The drug is used to treat a rare immunological condition involving mutated mast cells that affect the bone marrow, skin, gastrointestinal system, and other organs. Currently, Avapritinib is the only approved therapy for this specific disorder.
In addition to Avapritinib, Blueprint brings a promising research and development pipeline in immunology, a field that Sanofi has been actively investing in to diversify and innovate its therapeutic offerings.
Potential for Additional Payments
The agreement also includes potential milestone payments tied to the progress of Blueprint’s drug development efforts. If certain clinical milestones are achieved with a specific drug candidate, the total deal value could increase to as much as $9.5 billion.
Sanofi expects the acquisition to close in the third quarter of 2025. The company stated that the transaction is not anticipated to significantly affect its financial outlook for the year. Currently, Sanofi’s market capitalization stands at approximately €107 billion.
This acquisition highlights Sanofi’s commitment to expanding its presence in cutting-edge medical research and targeting niche markets within the pharmaceutical industry, particularly in areas where existing treatment options remain limited.
